Tandem Diabetes Care (TNDM) Competitors

Tandem Diabetes Care (NASDAQ:TNDM) and iRhythm Technologies (NASDAQ:IRTC) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends, community ranking and profitability.

Which has more volatility and risk, TNDM or IRTC?

Tandem Diabetes Care has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.

Does the MarketBeat Community believe in TNDM or IRTC?

Tandem Diabetes Care received 183 more outperform votes than iRhythm Technologies when rated by MarketBeat users. However, 66.04% of users gave iRhythm Technologies an outperform vote while only 61.18% of users gave Tandem Diabetes Care an outperform vote.

Company	Underperform	Outperform
Tandem Diabetes Care	Outperform Votes 572 61.18%	Underperform Votes 363 38.82%
iRhythm Technologies	Outperform Votes 389 66.04%	Underperform Votes 200 33.96%

Is TNDM or IRTC more profitable?

Tandem Diabetes Care has a net margin of -18.37% compared to iRhythm Technologies' net margin of -25.33%. Tandem Diabetes Care's return on equity of -34.38% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-18.37%	-34.38%	-10.91%
iRhythm Technologies	-25.33%	-69.87%	-23.50%

Which has higher valuation & earnings, TNDM or IRTC?

iRhythm Technologies has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$770.01M	4.30	-$222.61M	-$2.17	-23.61
iRhythm Technologies	$492.68M	5.57	-$123.41M	-$4.23	-20.85

Do analysts rate TNDM or IRTC?

Tandem Diabetes Care presently has a consensus target price of $50.58, suggesting a potential downside of 1.26%. iRhythm Technologies has a consensus target price of $134.00, suggesting a potential upside of 51.91%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, analysts clearly believe iRhythm Technologies is more favorable than Tandem Diabetes Care.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92
iRhythm Technologies	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to TNDM or IRTC?

In the previous week, Tandem Diabetes Care had 10 more articles in the media than iRhythm Technologies. MarketBeat recorded 14 mentions for Tandem Diabetes Care and 4 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.45 beat Tandem Diabetes Care's score of 0.87 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tandem Diabetes Care and iRhythm Technologies tied by winning 8 of the 16 factors compared between the two stocks.